(Reuters Health)—Age-adjusted hip fracture incidence has declined in the U.S. over the past four decades, aided by a decline in smoking and alcohol consumption, a new study suggests. Researchers examined data on 4,918 men and 5,634 women who participated in the prospective Framingham Heart Study from 1970 to 2010. Overall, the age-adjusted incidence of hip…
Articles by Natasha Yetman
Telemedicine Highlights Health Disparities During Pandemic
NEW YORK (Reuters Health)—The COVID-19 pandemic has accelerated the expansion of telemedicine across the U.S., which has opened up access to doctor’s offices for families with limited resources. But at the same time, the health disparity gap could continue to widen unless safeguards are put into place, according to a pair of new editorials. “There…
IL-1-Beta Blockade May Slow OA Progression
NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…
Tocilizumab Fails Late-Stage Trial for COVID-19
ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…
Denosumab Dosing Delays Tied to Increased Fracture Risk
NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…
Doctors Detail Kawasaki-Like Disease in Adult COVID-19 Patients
(Reuters Health)—During the COVID-19 pandemic, an inflammatory condition similar to Kawasaki disease has been reported in children and adolescents, and now two groups of New York doctors each describe a case, one in a 36-year-old woman and one in a 45-year-old man.1 “We’re still learning how COVID-19 is affecting children and adults. The better we…
FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis
HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…
Some Drug Trials Resume after Declines During Pandemic
(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters. The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials…
With Apps & Remote Medicine, Japan Offers Glimpse of Doctor Visits in Post-COVID-19 Era
TOKYO (Reuters)—The coronavirus crisis has prompted Japan to ease regulations on remote medical treatment, creating an opening for tech companies and offering a glimpse of the future of healthcare in the world’s most rapidly aging society. As coronavirus cases spiked in April, Japan temporarily eased restrictions on remote medical care, allowing doctors to conduct first-time…
Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 97
- Next Page »